FMA
ALNY icon

FNY Managed Accounts’s Alnylam Pharmaceuticals ALNY Stock Holding History

FNY Managed Accounts’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-218
Closed -$26.1K – 418
2015
Q2 		$26.1K Buy
+218
New +$26.1K 0.03% 189

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

FNY Managed Accounts's ALNY Position: Q3 2015 in Review

FNY Managed Accounts sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2015, closing a stake of 218 shares — an estimated $26.1K sold.

FNY Managed Accounts first reported a position in ALNY in Q2 2015 and held it in 1 quarter. The position peaked at $26.1K in Q2 2015. 258 funds tracked by Wall St. Rank hold ALNY as of Q3 2015.

  • FNY Managed Accounts reported no remaining Alnylam Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • FNY Managed Accounts sold 218 Alnylam Pharmaceuticals shares in Q3 2015, an estimated $26.1K.
  • FNY Managed Accounts first reported a position in Alnylam Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • FNY Managed Accounts's Alnylam Pharmaceuticals position peaked at $26.1K in Q2 2015.
  • 258 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2015.

Based on FNY Managed Accounts's 13F filing for Q3 2015, filed 27 Oct 2015.